查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842288

美國臨床實驗CDMO 市場規模、佔有率和趨勢分析報告：按服務、最終用途和細分市場預測，2025 年至 2033 年

U.S. Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Service (Contract Development, Contract Manufacturing), By End Use (Pharmaceutical Companies, Biotech Companies), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國臨床實驗CDMO市場摘要

美國臨床實驗試驗 CDMO 市場規模預計在 2024 年達到 18.2 億美元，預計到 2033 年將達到 35.8 億美元，2025 年至 2033 年的複合年成長率為 9.38%。

在美國，新藥臨床實驗(IND) CDMO 正在經歷顯著成長，這得益於廣泛而複雜的早期研發管線，尤其是在腫瘤學、罕見疾病和先進藥物等領域。

此外，新興生物製藥公司注重成本效益和快速的IND準備，因為它們依賴外部合作夥伴提供化學、生產和控制 (CMC) 以及非臨床和臨床材料。供應鏈韌性、對國內生產能力的偏好以及更快的監管響應等因素進一步推動了外包。平台流程的實施、結構化的技術轉移以及分階段的品質措施有助於降低專案風險，使全面的IND驗證成為一個利潤更高的外包市場。

此外，不斷擴展的技術進步，特別是在數位能力和特定於模式的方法方面的進步，正在促進市場成長。人工智慧輔助實驗設計 (DoE)、數位雙胞胎技術和自動批次記錄的採用有助於縮短時間表並提高執行準確性。在可行的情況下，一次性和連續處理方法的使用正在擴展到 I 期生產，同時正在採用高通量分析和先進的生物檢測測定來降低 CMC 包裝風險。透過流動化學、固體控制和製程分析技術 (PAT) 等技術，正在加強在 mRNA/脂質奈米顆粒 (LNP)、病毒載體、質體和高固體藥物成分 (HPAPI) 等各個領域的專業知識。此外，資料完整性正在透過電子品管系統 (eQMS) 和實驗室資訊管理系統 (LIMS) 緊密整合。

此外，對模組化良好生產規範 (GMP)、無菌填充能力、載體和質體生產能力、微流體LNP 平台以及可擴展品管(QC) 實驗室的投資不斷增加，正在支持市場成長。用於 IND 的毒理學和生物分析能力正在不斷擴展，以確保單一合約課責。正在進行策略性併購，以整合基本能力和地理冗餘，同時優先考慮新建和維修以加快速度。用於勞動力發展和技術人員培訓的資金旨在緩解生技藥品和無菌加工中的瓶頸。採用商業結構，包括基於里程碑的定價和預留產能選項，旨在緊密結合獎勵。

此外，監管格局受到FDA對ICH Q8-Q12中概述的分階段CMC、嚴格的資料完整性措施（編纂於21 CFR第11部分）以及明確定義的可比性策略的期望的影響。 IND前期合作正被用來確保控制策略、分析驗證方法和穩定性要求的一致性。快速通道、突破性療法和再生醫學先進療法(RMAT)等加速認定的採用，要求在開發早期就建立健全的流程和詳盡的文件記錄。對於無菌藥品，無菌處理和污染控制的標準從一開始就在製定中，並且實施數位審核追蹤和基於電腦軟體保障(CSA)的驗證已成為標準做法。因此，該行業正在出現提供全方位服務的IND推動者與高度專業化的提供者之間的分化。

營運框架正在不斷完善，以利用標準化平台、平行工作流程和整合計劃管理，這些對於縮短週期至關重要。優先供應商協議和長期主服務協議正變得越來越普遍，以確保優先獲得載體和無菌填充等有限資源。透過基於績效的收費模式和產能儲備所建立的風險分擔機制也越來越普遍。因此，預計市場將進一步整合和選擇性專業化，成長機會將惠及那些能夠展現數位化能力、跨模式深度和韌性的國內供應鏈的CDMO。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國臨床實驗CDMO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術格局
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析

第4章：美國臨床實驗CDMO 市場：服務估算與趨勢分析

  • 美國臨床實驗CDMO 市場（按服務）：細分儀表板
  • 美國臨床實驗CDMO市場（按服務）：波動分析
  • 按服務分類，2021-2033 年
  • 合約開發
    • 小分子
    • 高分子
  • 契約製造
    • 小分子
    • 高分子

第5章美國臨床實驗CDMO市場：最終用途估計與趨勢分析

  • 美國臨床實驗試驗 CDMO 市場（依最終用途）：細分儀表板
  • 美國臨床實驗CDMO 市場（依最終用途分類）：波動分析
  • 依最終用途，2021-2033年
  • 製藥公司
  • 生技公司
  • 其他

第6章 競爭態勢

  • 主要參與者分類
    • 市場領導者
    • 新興企業
  • 2024年市佔率/評級分析（熱圖分析）
  • 公司簡介
    • Catalent, Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Patheon Inc.
    • Covance
    • IQVIA Holdings Inc.
    • Cambrex Corporation
    • Charles River Laboratories International, Inc.
    • Syneos Health
    • Syngene International
    • Jubilant Pharmova
    • Piramal Pharma Solutions
    • Dr. Reddy's CPS
    • Dishman Carbogen Amcis
    • Biocon Biologics
    • Laurus Labs
Product Code: GVR-4-68040-736-1

U.S. Investigational New Drug CDMO Market Summary

The U.S. investigational new drug CDMO market size was estimated at USD 1.82 billion in 2024 and is projected to reach USD 3.58 billion by 2033, growing at a CAGR of 9.38% from 2025 to 2033. The Investigational New Drug (IND) CDMO is experiencing significant growth in the U.S., driven by an extensive and complex early-stage pipeline, particularly in areas such as oncology, rare diseases, and advanced modalities.

Besides, emerging biopharma companies are focusing on cost efficiency and swift IND readiness as they depend on external partners for Chemistry, Manufacturing, and Controls (CMC), as well as nonclinical and clinical materials. Aspects like supply-chain resilience, a preference for domestic capacity, and faster regulatory pathways are further encouraging outsourcing. The implementation of platform processes, structured tech transfers, and phase-appropriate quality measures has helped mitigate program risks, thereby making comprehensive IND enablement more favorable outsourcing market.

In addition, growing technological advancements, particularly in digital capabilities and modality-specific approaches, have contributed to market growth. The adoption of AI-assisted Design of Experiments (DoE), digital twin technology, and automated batch-recording is helping to shorten timelines and improve execution accuracy. The use of single-use and continuous processing methods is being extended into Phase I manufacturing where feasible, and high-throughput analytics and advanced bioassays are being employed to reduce CMC package risks. Expertise in various domains, such as mRNA/Lipid Nanoparticles (LNP), viral vectors, plasmids, and highly potent active pharmaceutical ingredients (HPAPI), has been enhanced through techniques, including flow chemistry, solid-state control, and Process Analytical Technology (PAT). Besides, data integrity is being firmly integrated through electronic Quality Management Systems (eQMS) and Laboratory Information Management Systems (LIMS).

Moreover, growing investments in modular Good Manufacturing Practice (GMP), aseptic fill-finish capabilities, vector, and plasmid production capacity, microfluidic LNP platforms, and expandable Quality Control (QC) laboratories support the market growth. IND-enabling toxicology and bioanalytical capabilities are being scaled up to ensure single-contract accountability. Strategic mergers and acquisitions are being undertaken to incorporate essential capabilities and geographic redundancy, while new builds and retrofits are being prioritized for speed. Funding for workforce development and technician training is aimed at alleviating bottlenecks in biologics and sterile operations. The adoption of commercial constructs that include milestone-based pricing and reserved capacity options is intended to align incentives closely.

Furthermore, the regulatory landscape is being influenced by FDA expectations regarding phase-appropriate CMC as outlined in ICH Q8-Q12, strict data integrity measures (coded as 21 CFR Part 11), and well-defined comparability strategies. Pre-IND engagements are being utilized to ensure alignment on control strategies, analytical validation methods, and stability requirements. Expedited designations such as Fast Track, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT) status are being employed, necessitating robust processes and thorough documentation early in development. Standards for sterile products regarding aseptic processing and contamination control practices are being established from the beginning, while the incorporation of digital audit trails and Computer Software Assurance (CSA)-based validation has become a standard practice. Thus, the industry is witnessing a divide between full-service IND enablers and hyper-specialized providers.

Operational frameworks are being refined to leverage standardized platforms, simultaneous workstreams, and integrated project management, which are key to reducing cycle times. Preferred-provider agreements and long-term master service contracts are gaining traction to ensure priority access to limited resources such as vectors and sterile filling. Risk-sharing mechanisms are being employed through success-fee models and capacity reservations. Hence, the market is likely to see further consolidation and selective specialization, with growth opportunities favoring CDMOs that can demonstrate digital sophistication, depth in various modalities, and resilient domestic supply chains, all while consistently achieving first-pass IND approvals.

U.S. Investigational New Drug CDMO Market Report Segmentation

This report forecasts revenue growth at and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. investigational new drug CDMO market report based on service and end use.

  • Service Outlook (Revenue, USD Million, 2021 - 2033
  • Contract Development
    • Small Molecule
    • Bioanalysis and DMPK Studies
    • Toxicology Testing
    • Pathology and Safety Pharmacology Studies
    • Drug Substance Development
    • Synthetic Route Development
    • Process Development
    • Form Selection Crystallization Process Development
    • Scale-up of Drug Substance
    • Formulation Development
    • Pre Formulation
    • Preclinical Formulation Selection
    • First In Man Formulation/ Process Development
    • Analytical & Quality Services
    • Analytical Method Development / Validation
    • Release Testing of Drug Substance and Drug Product
    • Formal Stability of Drug Substance and Drug Product
    • Process Optimization
    • Work Up Purification Steps
    • Telescoping & Process Refining
    • Initial Optimization
    • Large Molecule
    • Cell Line Development
    • Process Development
    • Upstream
    • Microbial
    • Mammalian
    • Others
    • Downstream
    • MABs
    • Recombinant Proteins
    • Others
  • Contract Manufacturing
    • Small Molecule
    • Oral Solids
    • Semi-Solids
    • Liquids & Injectables
    • Others
    • Large Molecule
    • MABs
    • Recombinant Proteins
    • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotech Companies
  • Others

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Investigational New Drug CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing outsourcing services by pharmaceutical companies
      • 3.2.1.2. Rising investment in R&D
      • 3.2.1.3. Growing pharmaceutical industry
      • 3.2.1.4. Stringent regulatory requirements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance issues while outsourcing
      • 3.2.2.2. Changing scenario in developing countries
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Investigational New Drug CDMO Market: Service Estimates & Trend Analysis

  • 4.1. U.S. Investigational New Drug CDMO Market, By Service: Segment Dashboard
  • 4.2. U.S. Investigational New Drug CDMO Market, By Service: Movement Analysis
  • 4.3. U.S. Investigational New Drug CDMO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 4.4. Contract Development
    • 4.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Small Molecule
      • 4.4.2.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Bioanalysis and DMPK Studies
        • 4.4.2.2.1. Bioanalysis and DMPK Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Toxicology Testing
        • 4.4.2.3.1. Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.4. Pathology and Safety Pharmacology Studies
        • 4.4.2.4.1. Pathology and Safety Pharmacology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.5. Drug Substance Development
        • 4.4.2.5.1. Drug Substance Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.5.2. Synthetic Route Development
          • 4.4.2.5.2.1. Synthetic Route Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.5.3. Process Development
          • 4.4.2.5.3.1. Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.5.4. Form Selection Crystallization Process Development
          • 4.4.2.5.4.1. Form Selection Crystallization Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.5.5. Scale-up of Drug Substance
          • 4.4.2.5.5.1. Scale-up of Drug Substance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.6. Formulation Development
        • 4.4.2.6.1. Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.6.2. Pre Formulation
          • 4.4.2.6.2.1. Pre Formulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.6.3. Preclinical Formulation Selection
          • 4.4.2.6.3.1. Preclinical Formulation Selection Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.6.4. First In Man Formulation/ Process Development
          • 4.4.2.6.4.1. First In Man Formulation/ Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.7. Analytical & Quality Services
        • 4.4.2.7.1. Analytical & Quality Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.7.2. Analytical Method Development / Validation
          • 4.4.2.7.2.1. Analytical Method Development / Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.7.3. Release Testing of Drug Substance and Drug Product
          • 4.4.2.7.3.1. Release Testing of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.7.4. Formal Stability of Drug Substance and Drug Product
          • 4.4.2.7.4.1. Formal Stability of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.8. Process Optimization
        • 4.4.2.8.1. Process Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.8.2. Work Up Purification Steps
          • 4.4.2.8.2.1. Work Up Purification Steps Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.8.3. Telescoping & Process Refining
          • 4.4.2.8.3.1. Telescoping & Process Refining Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.2.8.4. Initial Optimization
          • 4.4.2.8.4.1. Initial Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Large Molecule
      • 4.4.3.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2. Cell Line Development
        • 4.4.3.2.1. Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3. Process Development
        • 4.4.3.3.1. Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.2. Upstream
          • 4.4.3.3.2.1. Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.2.2. Microbial
            • 4.4.3.3.2.2.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.2.3. Mammalian
            • 4.4.3.3.2.3.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.2.4. Others
            • 4.4.3.3.2.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.3. Downstream
          • 4.4.3.3.3.1. Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.3.2. MABs
            • 4.4.3.3.3.2.1. MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.3.3. Recombinant Proteins
            • 4.4.3.3.3.3.1. Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
          • 4.4.3.3.3.4. Others
            • 4.4.3.3.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Contract Manufacturing
    • 4.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Small Molecule
      • 4.5.2.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.2. Oral Solids
        • 4.5.2.2.1. Oral Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.3. Semi-Solids
        • 4.5.2.3.1. Semi-Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.4. Liquids & Injectables
        • 4.5.2.4.1. Liquids & Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.5. Others
        • 4.5.2.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Large Molecule
      • 4.5.3.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.3.2. MABs
        • 4.5.3.2.1. MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.3.3. Recombinant Proteins
        • 4.5.3.3.1. Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.3.4. Others
        • 4.5.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Investigational New Drug CDMO Market: by End Use Estimates & Trend Analysis

  • 5.1. U.S. Investigational New Drug CDMO Market, by End Use: Segment Dashboard
  • 5.2. U.S. Investigational New Drug CDMO Market, by End Use: Movement Analysis
  • 5.3. U.S. Investigational New Drug CDMO Market Estimates & Forecasts, by End Use, 2021 - 2033 (USD Million)
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biotech Companies
    • 5.5.1. Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Key Participant Categorization
    • 6.1.1. Market Leaders
    • 6.1.2. Emerging Players
  • 6.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 6.3. Company Profiles
    • 6.3.1. Catalent, Inc.
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Service Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Lonza
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Service Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Recipharm AB
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Service Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Siegfried Holding AG
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Service Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Patheon Inc.
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Service Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Covance
      • 6.3.6.1. Company Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Service Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. IQVIA Holdings Inc.
      • 6.3.7.1. Company Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Service Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. Cambrex Corporation
      • 6.3.8.1. Company Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Service Benchmarking
      • 6.3.8.4. Strategic Initiatives
    • 6.3.9. Charles River Laboratories International, Inc.
      • 6.3.9.1. Company Overview
      • 6.3.9.2. Financial Performance
      • 6.3.9.3. Service Benchmarking
      • 6.3.9.4. Strategic Initiatives
    • 6.3.10. Syneos Health
      • 6.3.10.1. Company Overview
      • 6.3.10.2. Financial Performance
      • 6.3.10.3. Service Benchmarking
      • 6.3.10.4. Strategic Initiatives
    • 6.3.11. Syngene International
      • 6.3.11.1. Company Overview
      • 6.3.11.2. Financial Performance
      • 6.3.11.3. Service Benchmarking
      • 6.3.11.4. Strategic Initiatives
    • 6.3.12. Jubilant Pharmova
      • 6.3.12.1. Company Overview
      • 6.3.12.2. Financial Performance
      • 6.3.12.3. Service Benchmarking
      • 6.3.12.4. Strategic Initiatives
    • 6.3.13. Piramal Pharma Solutions
      • 6.3.13.1. Company Overview
      • 6.3.13.2. Financial Performance
      • 6.3.13.3. Service Benchmarking
      • 6.3.13.4. Strategic Initiatives
    • 6.3.14. Dr. Reddy's CPS
      • 6.3.14.1. Company Overview
      • 6.3.14.2. Financial Performance
      • 6.3.14.3. Service Benchmarking
      • 6.3.14.4. Strategic Initiatives
    • 6.3.15. Dishman Carbogen Amcis
      • 6.3.15.1. Company Overview
      • 6.3.15.2. Financial Performance
      • 6.3.15.3. Service Benchmarking
      • 6.3.15.4. Strategic Initiatives
    • 6.3.16. Biocon Biologics
      • 6.3.16.1. Company Overview
      • 6.3.16.2. Financial Performance
      • 6.3.16.3. Service Benchmarking
      • 6.3.16.4. Strategic Initiatives
    • 6.3.17. Laurus Labs
      • 6.3.17.1. Company Overview
      • 6.3.17.2. Financial Performance
      • 6.3.17.3. Service Benchmarking
      • 6.3.17.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 US Investigational New Drug CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 4 US Investigational New Drug CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Investigational New Drug CDMO Market Dynamics
  • Fig. 17 Porter's Five Forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Investigational New Drug CDMO Market: Service outlook and key takeaways
  • Fig. 20 U.S. Investigational New Drug CDMO Market: Service movement analysis
  • Fig. 21 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Bioanalysis and DMPK Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Pathology and Safety Pharmacology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Drug Substance Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Synthetic Route Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Form Selection Crystallization Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Scale-up of Drug Substance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Pre Formulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Preclinical Formulation Selection Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 First In Man Formulation/ Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Analytical & Quality Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Analytical Method Development / Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Release Testing of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Formal Stability of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Process Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Work Up Purification Steps Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Telescoping & Process Refining Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Initial Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Oral Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Semi-Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Liquids & Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 U.S. Investigational New Drug CDMO Market: End Use outlook and key takeaways
  • Fig. 65 U.S. Investigational New Drug CDMO Market: End Use movement analysis
  • Fig. 66 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key company categorization
  • Fig. 70 Service heat map analysis
  • Fig. 71 Strategic framework